Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
KnipBio (now rebranded as Knip) is a Massachusetts-based biotechnology company specializing in sustainable aquaculture feed solutions. Founded in 2013, the company utilizes a proprietary precision fermentation platform, PROTEINplus, to produce single-cell protein (SCP) ingredients from naturally occurring microbes, specifically the leaf symbiont Methylobacterium extorquens. Its flagship products, including KnipBio Meal and JUV, are designed to enhance fish and shrimp health, improve stress resilience, and provide essential nutrients like bio-astaxanthin. By replacing traditional fishmeal with sustainable, traceable alternatives, KnipBio aims to improve farm profitability and reduce the environmental footprint of the global aquaculture industry. The company has achieved significant regulatory milestones, including being the first to receive FDA GRAS status for a single-cell protein in aquaculture.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on KnipBio.